The Impact of a Forced Non-Medical Switch of Inhaled Respiratory Medication Among Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Patient Survey on Experience with Switch, Therapy Satisfaction, and Disease Control.

摘要: Purpose Budesonide/formoterol pressurized metered-dose inhaler (pMDI) was removed from a Medicare Part D formulary, and patients switched to fluticasone-based dry powder (DPI) therapies. This study describes the experience, satisfaction, disease control among with asthma or chronic obstructive pulmonary (COPD) who due removal formulary. Patients Methods A patient survey conducted adults COPD used budesonide/formoterol pMDI for ≥3 months prior formulary block new medication weeks after switching, recruited by providers in research panel. Survey comprised both validated instruments (PASAPQ, OEQ, ACQ-6, CAT) stand-alone questions. Patient characteristics, switch device treatment onset of effect, were compared between (asthma COPD) (once twice daily) cohorts. Minimal significance group differences: P≤0.05. Results Among 100 patients, 93% received communication their doctor nurse about 73% training on using inhaler. an average 7 completing survey. satisfaction therapy high (PASAPQ; mean overall satisfaction: 6.2 asthma; 6.0 COPD; P=0.338). However, not well controlled (ACQ-6) 62% asthma, 56% reported high/very impact illness lives (CAT). Sixty-eight percent 70% COPD, respectively, required reliever (≥3 puffs) most days during week There no significant differences (ACQ-6, once-daily twice-daily treatments (P>0.05 COPD). Conclusion Even when reporting medication, objective measures showed substantial morbidity, regardless DPI dosing regimen.